Adults: Nplate® is indicated for the treatment of primary immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).

Pediatrics: Nplate® is indicated for the treatment of chronic primary immune thrombocytopenia (ITP) in paediatric patients one year of age and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).
For full details please refer to the PI as approved by the IL MoH. License Holder: Amgen Europe B.V., Israel Branch|

TAVALISSE® is indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments.
For full details please refer to the Israeli PI as approved by the MoH. TAVALISSE is a trademark of Rigel Pharmaceuticals, Inc.